Nkarta, Inc. (NKTX)

Market Cap	133.48M
Revenue (ttm)	n/a
Net Income (ttm)	-122.33M
Shares Out	49.07M
EPS (ttm)	-2.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	526,096
Open	2.57
Previous Close	2.64
Day's Range	2.49 - 2.74
52-Week Range	1.28 - 9.20
Beta	-0.11
Analysts	Strong Buy
Price Target	13.00 (+377.94%)
Earnings Date	Nov 9, 2023

About NKTX

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX01...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 10, 2020
• Employees: 167
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTX

Analyst Forecast

According to 6 analysts, the average rating for NKTX stock is "Strong Buy." The 12-month stock price forecast is $13.0, which is an increase of 377.94% from the latest price.

Price Target

$13.0

(377.94% upside)

Analyst Consensus: Strong Buy